Amicus Eyes Breakthrough Drug, PRV Revenue In Scioderm Buy
This article was originally published in Scrip
Executive Summary
Amicus Therapeutics chairman and CEO John Crowley had special insight into the value of Scioderm's topical drug candidate Zorblisa (SD-101) – he's been a member of the small, private company's board of directors for two years and became convinced that Amicus could add value to the "breakthrough" treatment for epidermolysis bullosa (EB).
You may also be interested in...
Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure
CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.
Amryt Pharma: EIB Funds Secure Phase III For Rare Skin Disease Candidate And Cholesterol Drug License
Not many 18-month old rare and orphan disease-focused biotech companies have an approved product in their portfolio. Even fewer have persuaded the European Investment Bank to make a direct investment into their business. Amryt Pharma can claim both.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.